Prana Biotechnology gets green light for Alzheimer's clinical trial
News | 12 September 2012
Prana Biotechnology (ASX: PBT, NASDAQ: PRAN) has received a recommendation from the Data Safety Monitoring Board that its clinical trial of PBT2 to treat Alzheimer's disease continue as planned following an initial review of clinical data. The 12-month ...
Click on the link to read the full article at Proactive Investors Australia
(This link will open in a new window)
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
